ImmunoGen Inc

• Country

  United States of America

• Sector

  Health Care

• Industry group

  Pharmaceuticals, Biotechnology & Life Sciences

• Industry

  Biotechnology

• Sub-sector

  Health Care

• Capitalization (millions of $)

  8724.2

• Ticker

  IMGN.O

• ISIN

  US45253H1014

• IPO date

• Availability on Russian exchanges

  No

• Reporting for

  2023-11-02

• Date fact. publication of reports

  2023-09-30

ImmunoGen, Inc. is a clinical-stage biotechnology company focused on developing the antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of its potent anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine (IMGN853), IMGN632, MGC936 and IMGN151. Its Mirvetuximab soravtansine is a first-in-class ADC comprising a folate receptor alpha (FR?)-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin-targeting agent to kill the targeted cancer cells. IMGN632 is an ADC comprised of a high-affinity antibody designed to target CD123 for patients with hematological malignancies, including blastic plasmacytoid dendritic cell neoplasm (BPDCN), acute myeloid leukemia (AML), and acute lymphocytic leukemia (ALL).